SEC Comment Letter for Enlivex Ltd. (ENLV) (CIK 0001596812) (ENLV) — Feb 3, 2020

Enlivex Ltd. (ENLV) (CIK 0001596812)
Date: Feb. 3, 2020 · CIK: 0001596812 · Accession: 0000000000-20-000993

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-36578

Date

February 3, 2020

Author

Shachar Schlosberger

Form

UPLOAD

Company

Enlivex Ltd. (ENLV) (CIK 0001596812)

Letter

February 3, 2020 Shachar Schlosberger Chief Financial Officer Enlivex Therapeutics Ltd. 14 Einstein Street Nes Ziona, Israel 7403618 Re:Enlivex Therapeutics Ltd. Form 20-F for the year ended December 31, 2018 Filed on April 30, 2019 Form 20-F/A for the year ended December 31, 2018 Filed on January 23, 2020 File No. 001-36578 Dear Ms. Schlosberger: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

February 3, 2020
Shachar Schlosberger
Chief Financial Officer
Enlivex Therapeutics Ltd.
14 Einstein Street
Nes Ziona, Israel 7403618
Re:Enlivex Therapeutics Ltd.
Form 20-F for the year ended December 31, 2018
Filed on April 30, 2019
Form 20-F/A for the year ended December 31, 2018
Filed on January 23, 2020
File No. 001-36578
Dear Ms. Schlosberger:
            We have completed our review of your filings.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io